Research & Development
Castle Biosciences completes $65M AltheaDx acquisition
Under the terms of the definitive agreement, AltheaDx became a subsidiary of Castle Biosciences. At closing, Castle paid $65 million to AltheaDx security holders, which consisted of $32.5 million in cash and $32.5 million in Castle common stock.
April 26, 2022
Blood test could identify risk of psychotic disorders
The findings could help clinicians better assess and treat patients, wrote a team led by David Cotter, PhD, of the Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences in Dublin, Ireland.
August 27, 2020
Poor oral care may affect the accuracy of COVID-19 tests
Patients who didn't brush or rinse their teeth may have allowed noninfectious viral nucleic acid to build up, resulting in prolonged viral shedding. On average, those who didn't keep their oral cavities clean continued to shed the virus for an additional two weeks and resulted in more positive real-time reverse transcription polymerase chain reaction (PCR) tests, the authors wrote.
August 3, 2020
Failed study leaves CRP test hanging as biomarker in bipolar depression
The results leave the potential role of CRP as a biomarker up in the air. They also highlight the broader challenges in developing biomarkers and personalized treatments in the field of psychiatry.
May 7, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Page 1 of 1